Thrombophilia and antithrombotic prevention in gynecology and obstetrics;Thrombophilie und antithrombotische Pravention in Gynakologie und Geburtshilfe

Internist

Volumn 38, Issue 7, 1997, Pages 650-657

  Winkler, D H ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DESOGESTREL; ESTROGEN; ETHINYLESTRADIOL; GESTODENE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; ORAL CONTRACEPTIVE AGENT;

EMBOLISM; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PREGNANCY; REVIEW; RISK FACTOR; THROMBOPHILIA; THROMBOSIS; THROMBOSIS PREVENTION; ESTROGEN THERAPY; FEMALE; PREGNANCY COMPLICATION; THROMBOEMBOLISM;

CONTRACEPTIVES, ORAL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; RISK FACTORS; THROMBOEMBOLISM;

EID: 0030858335     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001080050076     Document Type: Review

References (57)

1. Badaracco MA, Vessey MP (1974) Recurrence of venous thromboembolism disease and use of oral contraceptives. Br Med J 1:215-217
2. Barbour LA, Kick SD, Steiner JF (1994) A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Am J Obstet Gynecol 170:862-869
3. Beller FK, Ebert C (1985) Effects of oral contraceptives on blood coagulation. A review. Obestet Gynectol Surv 40:425-436
4. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH (1994) Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369:64-67
5. Bertina RM, Reitsma PH, Rosendaal FR, Vandenbroucke JP (1995) Resistance to activated protein C and factor V leiden as risk factors for venous thrombosis. Thromb Hae mostas 74:449-453
6. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Büller HR,Vandenbroucke JP (1995) Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 346:1593-1596
7. Böttiger LE, Westerholm B (1971) Oral contraceptives and thromboembolic disease. Swedish experience. Acta Med Scand 10:455-463
8. Bush TL (1996) Evidence for primary and secondary prevention of coronary artery disease in women taking oestrogen replacement therapy. Eur Heart J 17D:9-14
9. Caine YG, Bauer KA, Barzegar E, ten Cate H, Sacks FM, Walsh BW, Schiff I, Rosen berg RD (1992) Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemostas 68:392-395
10. Copplestone A, Oscier DG (1987) Heparin-induced thrombocytopenia in pregnancy. Br J Haematol 65:248
11. Dahlbäck B, Carlsson M, Svensson PJ (1993) Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 80:1004-1008
12. Dahlmann TC, Lindvall N, Hellgren M (1990) Osteopenia pregnancy during long-term heparin treatment: a radiological study post partum. Br J Obstet Gynaecol 97:221-228
13. Daly E,Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S (1996) Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 348:977-980
14. DeSwiet M (1983) Prolonged heparin therapy in pregnancy causes bone demineralization. Br J Obstet Gynaecol 90:1129-1134
15. Fotherby K (1989) The progestogen-only pill thrombosis. Br J Fam Plan 15:83-85
16. Gerstman BB, Piper JM, Freiman JP, Tomita DK, Kennedy DL, Ferguson WJ, Bennett RC (1990) Oral contraceptive oestrogen and progestin potencies and the incidence of deep venous thromboembolism. Int J Epidemiol 19:931-936
17. Gerstmann BB, Piper JM, Tomita DK, Ferguson WJ, Stadel BV, Lundin FE (1991) Oral contraceptives estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidem 177:32-37
18. Ginsberg JS, Hirsh J, Rainbow AJ, Coates G (1989) Risks to the fetus of radiological procedures used in the diagnosis of maternal venous thromboembolic disease. Thromb Haemostas 61:189-196
19. Ginsberg JS, Hirsh J (1989) Anticoagulants during pregnancy. Ann Rev Med 40:79-86
20. Ginsberg JS, Hirsh J (1992) Use of antithrombotic agents during pregnancy. Chest 102, 4:385-390
21. Greer IA (1991) The problem and prophylaxis of thromboembolism in pregnancy. Curr Med Lit Throm 1:131-138
22. Greer IA (1989) Thromboembolic problems in pregnancy. Fetal Med Rev 1:79-103
23. Greinacher A, Mueller-Eckhardt C (1991) Therapie der Heparin-assoziierten Thrombozytopenie. Dtsch Med Wschr 116:1483-1484
24. Greinacher A, Eckhardt T, Mumann J, Müller-Eckhardt C (1993) Pregnancy complicated by heparin associated thrombocytopenioa: Management by prospectively in vitro selected heparinoid (Org 10172). Thromb Res 71:123-126
25. Greinacher A, Mueller-Eckhardt C (1991) Diagnostik der Heparin-assoziierten Thrombozytopenie. Dtsch Med Wschr 116:1479-1482
26. Her Majesty Stationery Office (1995) Annual Hospital In-Patients Inquiries for Endland and Wales
27. Jick H, Jick SS, Gurewich W, Myers MW, Vasilakis C (1995) Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 346:1589-1593
28. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM (1996) Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 348:981-983
29. Kierkegaard A (1980) Incidence of acute deep vein thrombosis in two districts. Acta Chir Scand 146:267-269
30. Koeleman BPC, Reitsma PH, Allaart CF, Bertina RM (1994) APC-resistance as an additional risk factor for thrombosis in protein C deficient families. Blood 84:1031-1035
31. Koster T, Small RA, Rosendaal FR, Helmerhorst FM (1995) Oral contraceptives and venous thromboembolism: a quantitative discussion of the uncertainties. J Intern Med 238:31-37
32. Lidegaard O, Milsom I (1996) Oral contraceptives and thrombotic diseases: impact of new epidemiolical studies. Contraception 53:135-139
33. Mammen EF (1982) Oral contraceptives and blood coagulation: A citical review. Am J Obest Gynecol 142:781-790
34. Meytes D, Ayalon H, Virag I, Weisbort Y, Zakut H (1986) Heparin induced thrombocytopenia and recurrent thrombosis in pregnancy. A case report. J Reprod Med 31:993-996
35. National Institutes of Health Consensus Development Conference (1986) Prevention of venous thrombosis and pulmonary embolism. JAMA 256:744-749
36. Pabinger I, Kyrle PA, Heistinger M, Eichinger S, Wittmann E, Lechner K (1994) The risk of thromboembolism in asymptomatic patients with protein C and protein S deficiency: A prospective cohort study. Thromb Haemos 71:441-445
37. Pabinger I, Schneider B, and the GTH Study Group on Natural Inhibitors (1994) Thrombotic risk of women with hereditary antithrombin III, protein C- and protein S deficiency taking oral contraceptives. Thromb Haemostas 71:548-552
38. Pabinger I, Brücker S, Kyrle PA, Scheider P, Kominger HC, Niessner H, Lechner K (1992) Hereditary deficiency of antithrombin III, protein C and protein S: prevalence in patients with a history of venous thrombosis and critera for rational patient screening. Blood Coag Fibrin 3:547-553
39. Report on confidential inquiries into maternal deaths in England and Wales, 1976-1978 (1982) London: Department of Health and Social Security
40. Rintelen C, Pabinger I, Knoebl P, Lechner K, Mannhalter C (1995) Oral contraceptives are the most important precipitating factors for venous thrombosis in young females homozygous for Arg 506 Gin mutation in the factor V gene. Blood 86:200
41. Scharf RE, Greinacher A, Riess H, Bredding HK (1994) Stellungnahme zur Entscheidung der Arzneimittelkommission der Deutschen Ärzteschaft vom 9.10.1992. Dtsch Ärztebl 91, 24:1121-1122
42. Sipes SL, Weiner CP (1990) Venous thromboembolic disease in pregnancy. Semin Perinatol 14:103-118
43. Spitzer WO, Lewis MA, Heinemann LAJ, Thorogood M, MacRae KD n behalf of Transnational Research Group on Oral Contraceptives and the Health of Young Women (1996) Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. BMJ 312:83-88
44. Tengborn L, Bergqvist D, Matzsch T, Bergqvist A, Hednar V (1989) Recurrent thromboembolism in pregnancy and puerperium. Is there a need for thromboprophylaxis? Am J Gynecol 160:90-95
45. Thromboembolic Risk Factors (THRIFT) Consensus Group (1992) Risk of and prophylaxis for venous thromboembolism in hospital patients. BMJ 305:567-574
46. Toglia MR, Weg JG (1996) Venous thromboembolism during pregnancy. N Engl J Med 335:108-114
47. Vessey M, Mant D, Smith A, Yeates (1986) Oral contraceptives and venous thromboembolism: findings in a large prospective study. BMJ 292:526
48. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Tech M, Gent M, Kelton JP (1995) Heparin-induced thrombocytopenia in patients treated with low molecular-weight heparin or unfractionated heparin. N Engl J Med 332:1330-1335
49. WHO Collaborative Study of cardiovascular disease and steroid hormone contraception (1995) Results of international multicentre case-control study. Lancet 346:1575-1582
50. WHO collaborative study of cardiovascular disease and steroid hormone contraception (1995) Effect of different progestogens in low oestrogenoral contraceptives on venous thromboembolic disease. Lancet 346:1285-1288
51. Winkler UH, APC Resistenz, Antithrombin III-, Protein C- oder S-Mangel (1997) Zur Abschätzung der Thrombosegefährdung bei Anwenderinnen oraler Kontrazeptiva. Geb Fra accepted for publication
52. Winkler UH (1996) Zur Prophylaxe und Behandlung der Thrombose in der Schwangerschaft. Gebfra 56:301-312
53. Winkler UH, Hölscher T, Schulte H, Zierleyn, Collet W, Schindlet AE (1996) Ethinylestradiol 20 μg versus 30 μ combined with 150 μg desogestrel: A large comparative study of the effects of two low dose oral contraceptives on the hemostatic system. Gynecol Endocrinol 10:265-271
54. Winkler UH (1996) Hormone replacement therapy and hemostasis: principles of a complex interaction. Maturitas 24:131-145
55. Winkler UH, Schindler AE, Endrikat J, Düsterberg B (1996) A comparative study of the effects on the hemostatic system of two monophasic gestodene oral contraceptives containing 20 μg and 30 μg ethinylestradiol. Contraception 53:75-84
56. Winkler UH (1997) Thromboembolierisiko, hormonelle Kontrazeption und Östrogensubstitution. Der Gynäkologe in Druck
57. Zöller B, Dahlbäck B (1994) Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 343:1536-1538